Voluntary announcement first patient dosed in phase II clinical trial of tinengotinib in combination with novel hormonal therapy for pretreated and progressed metastatic castration-resistant prostate cancer in China
Filed with HKEX · Stock code 2617 · · 2 pages · English
TransThera Sciences (Nanjing), Inc. 藥捷安康（南京）科技股份有限公司 (A joint stock company incorporated in the People’s Republic of China with limited liability) (Stock Code: 2617) VOLUNTARY ANNOUNCEMENT FIRST PATIENT DOSED IN PHASE II CLINICAL TRIAL OF TINENGOTINIB IN COMBINATION WITH NOVEL HORMONAL THERAPY FOR PRETREATED AND PROGRESSED METASTATIC CASTRATION- RESISTANT PROSTATE CANCER IN CHINA This announcement
TransThera Sciences (Nanjing). Inc. on 6ix
Earlier from TransThera Sciences (Nanjing)
- Voluntary announcement inclusion of yochanra (tinengotinib) in the CSCO guidelines for the diagnosis and treatment of biliary tract cancers (2026)
- New drug application for Tinengotinib tablets accepted by the national medical products administration
- TransThera Publishes Clinical Studies of Tinengotinib (TT-00420) against Cholangiocarcinoma on Lancet
- Inclusion of Tinengotinib tablets in the list of products for priority review by the national medical products administration
Later from TransThera Sciences (Nanjing)
- Interim report 2026
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Voluntary announcement business update on commercialisation of core product yochanra
- Next Day Disclosure Return
Follow TransThera Sciences (Nanjing) into a list and get an email when it puts out news.
Follow TransThera Sciences (Nanjing)